SOURCE: Leerink Swann

June 04, 2007 08:00 ET

Leerink Swann Appoints Daniel Yamron as Managing Director, Equity Capital Markets

BOSTON, MA--(Marketwire - June 4, 2007) - Healthcare investment bank Leerink Swann appointed Daniel Yamron as Managing Director, Equity Capital Markets.

"Dan brings an extensive track record of success from each of his capital markets leadership roles," said David Ogens, Head of Investment Banking at Leerink Swann. "His experience and expertise will further enhance Leerink Swann's ability to deliver the best outcomes for our clients."

Mr. Yamron has over twenty years of experience pricing securities, allocating transactions, and trading in the equities markets. Most recently, he founded and ran a capital markets advisory business that provided private placement execution skills to emerging growth companies. Prior to that, he directed Piper Jaffray's equity transactions business for the healthcare and financials verticals.

Mr. Yamron also helped to develop and grow Piper's alternative equity financing capability, with responsibilities for several new products including bought deals, registered direct offerings and PIPEs. Prior to that, Mr. Yamron was a Managing Director at CIBC and guided the firm to a leading underwriting presence during the 1999-2000 biotech bull market. In the mid 1990s, as Managing Director at Cowen and Company, he led Cowen's healthcare transactions practice.

Mr. Yamron began his career as a block trader at PaineWebber. He spent seven years trading stocks and derivatives of companies in a variety of industry groups. Mr. Yamron is a graduate of Carleton College and Harvard Business School.

About Leerink Swann

Leerink Swann is a healthcare-focused investment banking firm that provides equity research, corporate finance, asset management, and strategic advisory services for institutional, life sciences, and high-net-worth clients. For the past six years, Institutional Investor has named Leerink Swann "Best of the Boutiques" in Biotechnology, Healthcare Technology & Distribution, Medical Supplies and Devices, Pharmaceuticals/Major, and Pharmaceuticals/Specialty. Through its MEDACorp division, Leerink Swann provides biomedical-consulting services to the institutional investment community. With an internal team of experts and a dedicated external network of academic and community healthcare professionals, MEDACorp assesses the viability of cutting-edge medical technologies, thus giving decision makers the information they need to perform. Leerink Swann is a member NASD/SIPC.

Contact Information